McKesson, the largest U.S. pharmaceutical distributor, is facing some major headwinds these days. After years of strong sales growth thanks to generic drug price inflation, that tailwind is expected to slow and cut into the company’s overall revenue growth this year. McKesson also recently lost a handful of customers and could potentially lose another $13 billion worth of revenue in 2018 when (or if) Rite Aid is acquired by Walgreens. Management has been working on a series of maneuvers to lessen these blows, including acquiring strategic bolt-on companies to replace lost business and implementing a restructuring plan that’s expected to generate about $180 million in savings this fiscal year.
News about McKesson
John Hammergren is retiring after nearly two decades on the job.
The decision to sue is seen as an acknowledgment opioid makers won’t get serious about settling until the cases go to trial.
The president's drug price proposals didn't shake big pharma and other health care companies.
Attorney General Jeff Sessions announced a "statement of intent" to prop up suits against opioid makers and distributors.
Sparking a selloff in the shares of a host of health care-related companies.
Videos about McKesson
How health care is playing a larger role in the economy and on this year’s Fortune 500 list.